Page results
-
A research team involving UCLH clinicians has found a way to reduce the side effects of treatment for a disorder of the adrenal glands.
-
Outcome of National Institute for Health and Care Excellence (NICE) Technology Appraisal for Exagamglogene autotemcel (Exa-cel) for treating transfusion- dependent beta thalassaemia [ID4015] in individuals 12 years and over.
-
This page is for patients who have been referred on a suspected cancer pathway.
-
At UCLH we run seasonal COVID-19 vaccination clinics from our Hospital Hub within UCH. Vaccinations are available to members of the eligible public as well as UCLH patients.
-
Short videos on managing cancer pain, cancer-related fatigue and improving sleep
-
Our Getting Ready for Transition (GReaT) to secondary school parent information session will run on Wednesday 29 January 2025.
-
This page offers advice to patients who are feeling sick.
-
Bed availability is a “significant” factor in determining whether or not a patient is admitted to a critical care bed after surgery, questioning whether some are getting the care they need, a new study from researchers at UCL and UCLH has found for the first time.
-
Pfizer Limited, in agreement with the Medicines Healthcare products Regulatory Agency (MHRA), has withdrawn the product, while a review of the benefits and risks is carried out.
-
This page is for patients with obesity who are waiting for scheduled surgery.
File results
-
FOI/2023/0310 - Biologic treatment/ medicines in dermatology
-
FOI/2023/0313 - Consent, confidentiality and information sharing in mental healthcare and suicide
-
FOI/2023/0315 - Menopause Lead at the Trust
-
FOI/2023/0319 - Multiple Sclerosis (MS) treatment/ medication for any diseases
-
FOI/2023/0323 - Medications/ treatment for dermatology and respiratory medicine
-
FOI/2023/0336 - Number of pagers currently in use at the Trust
-
FOI/2023/0342 - Self-administration of medication policies
-
FOI/2023/0337 - Trac systems e-recruitment software used at the Trust
-
FOI/2023/0304 - Chronic lymphocytic leukaemia treatments
-
FOI/2023/0330 - Outsourced/ in-house occupational health provisions